The first manufacturing service of its kind delivers tested sterile, non-GMP media designed for feasibility testing before scale-up, to support development of cell and gene therapies
The DimAb™ development platform is different from traditional hybridoma fusion technologies in that it can directly isolate IgG genes from B cells of immunized animals